US7572834 — Rasagiline formulations and processes for their preparation
Formulation · Assigned to Teva Pharmaceutical Industries Ltd · Expires 2026-12-05 · 1y remaining
What this patent protects
This patent protects a pharmaceutical composition containing rasagiline mesylate and a specific compound, with a carrier, in a formulation with a certain concentration of the compound.
USPTO Abstract
The subject invention provides a pharmaceutical composition comprising N-propargyl-1(R)-aminoindan mesylate; a pharmaceutically acceptable carrier; and greater than 0.7 ppm but less than 30 ppm in total of a compound having the structure: and any salts of the compound.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.